• Molecular NameOxymorphone
  • Synonym14-Hydroxydihydromorphinone; Dihydrohydroxymorphinone; Dihydroxymorphinone; EN3202; Oximorphonum; Oxymorphine; oxymorphone
  • Weight301.342
  • Drugbank_IDDB01192
  • ACS_NO76-41-5
  • Show 3D model
  • LogP (experiment)0.83
  • LogP (predicted, AB/LogP v2.0)0.94
  • pka8.5, 9.3
  • LogD (pH=7, predicted)-0.15
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.14
  • LogSw (predicted, AB/LogsW2.0)6.24
  • Sw (mg/ml) (predicted, ACD/Labs)6.78
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds0
  • TPSA70.0
  • StatusFDA approved
  • AdministrationIntravenous, intramusucular, subcutaneous, oral, rectal
  • PharmacologyA powerful semi-synthetic opioid analgesic first developed in Germany circa 1914, patented in the USA by Endo Pharmaceuticals in 1955 and introduced to the United States market in January 1959 and other countries around the same time.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability10.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life1.3 +/- 0.7 hrs (with parenteral admin); 7.25-9.43 hr (with oral admin)
  • Excretion35% urine, 65% feces
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A